Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Researchers looked at data from more than 430,000 patients aged 50 and older who took either a GLP-1, sodium-glucose cotransporter 2 inhibitors (SGLT2i), metformin or insulin to manage their diabetes for at least two years
Here's what you need to know: Medicare Coverage (Effective Mid-2026) Following the November 2025 Trump administration agreements, Medicare will cover GLP-1 medications for obesity with: $50 monthly copay for eligible patients $245 government cost (down from $1,000+ list prices) Medicare Eligibility Requirements: BMI over 27 with prediabetes OR established cardiovascular disease, OR BMI over 30 with uncontrolled hypertension, kidney disease, or heart failure, OR BMI over 35 (severe obesity) Medicaid Coverage States can opt into $245 monthly pricing for all covered uses
529 3-Methyladenine (3-MA), a widely used inhibitor that blocks autophagosome formation, continues to serve as a mechanistic tool compound for dissecting autophagys role in autoimmune pathology
Annual List Review Process WADA leads an annual revision process concerning the List, beginning with an initial meeting in January and concluding with the publication of the List by 1 October
US$ 28.60
US$ 26.33
US$ 28.06
US$ 28.57
US$ 22.00
US$ 24.87
US$ 26.03
